---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Executive summary: Disease burden"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Disease burden. 1 evidence topic quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary/disease-burden"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Executive summary: Disease burden

<a id="heading-1.1.1"></a>

## 1.1.1 Burden of Generalized myasthenia gravis

<a id="topic-1.1.1-1"></a>

### Summary

The US estimates are for myasthenia gravis as a whole. In 2021 US claims and electronic health records, the diagnosed prevalence was 37.0 per 100,000 persons and the incidence 3.1 per 100,000 persons, and a separate claims analysis estimated approximately 82,715 US adults living with myasthenia gravis in 2021. A global meta-analysis of 63 articles estimated a prevalence of 12.4 (95% CI 10.6 to 14.5) per 100,000 population. Generalized disease specifically was measured in one cohort, where the 2019 prevalence was 11.18 and the incidence 2.95 per 100,000 population. Up to 80% of patients with ocular onset develop generalized symptoms, usually within two years, and approximately one third of patients with generalized disease have an exacerbation in a given year. Among hospitalizations from 2010 to 2019, the in-hospital mortality rate averaged 1.8%, and mortality averaged 5.0% among patients aged 65 years or older; in a separate cohort, 5-year overall survival was 75%, declining to 39% among those with crisis.

Among 841 participants from seven countries, mean baseline EQ-5D-5L utility was 0.817, 0.766, 0.648, and 0.530 for MGFA classes I to IV; in a larger MRW cohort (n = 1859), average EQ-5D-5L utility was 0.739, compared with 0.843 in POPUP. In Komodo Research data from 2017 to 2023, mean annual all-cause total health care costs in adults with newly diagnosed generalized myasthenia gravis were $58,341, compared with $14,469 in the non-MG cohort, with 59.3% of the difference driven by pharmacy costs (mostly immunoglobulin). Annual all-cause costs were $76,381 with any glucocorticoid use and $35,309 without, and mean monthly costs were $17,330 in a subgroup with exacerbation or crisis.

Source: [Rodrigues et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38040629/); [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10907989/); [Salari et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8686543/); [Herr et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10327564/); [Dresser et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8196750/); [Grover et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724412/); [Habib et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38165317/); [Barnett-Tapia et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13498700/); [Dewilde et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9890761/); [Dewilde et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10499690/); [Grover et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13293495/); [Silvestri et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13008238/); [Zhdanava et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38745448/)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
